Information Provided By:
News For MNTA;HRTX;PRNB;SNY From the Last 2 Days
Dec 1, 2021 | 06:54 EST
Sanofi announced it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne. "With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline. The transaction will add ORI-001 to Sanofi's early-stage pipeline. ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Ph1/2 trial to start in 2023," the company stated. The acquisition is expected to close early December 2021.
Nov 30, 2021 | 09:07 EST
In its continuing efforts to support gender equity in the workplace, Sanofi is offering all employees worldwide 14 weeks of paid parental leave starting January 1, 2022. This enhanced paid leave will cover all permanent employees who are welcoming a new child or whose partner is welcoming a new child, through childbirth, adoption, surrogacy, or due to custody. Employees will continue to receive their base salary for the 14-week leave period. This benefit is designed to support families by giving parents dedicated time to prepare for and welcome their new child. Sanofi's new global framework will provide a minimum benefit of paid parental leave so that all employees worldwide receive at least the same amount of paid time off. The new framework will not change or decrease existing benefits in countries that already offer more than 14 weeks of paid parental leave. For Sanofi employees in the United States, this means parental paid time off is increasing from 8 to 14 weeks.